Activity Overview
Neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) are significant drivers of vision loss in the United States, and they put substantial burdens on patients—both from the disease itself and the need for regular treatment.
Less-frequent injection protocols using newer anti-VEGF agents can reduce treatment burden for patients and their caregivers without compromising efficacy. In this program, expert faculty will review cases that illustrate the possibilities for providing extended treatment intervals for patients with neovascular retinal diseases.
Target Audience
This educational activity is directed toward retina specialists, comprehensive ophthalmologists, and optometrists involved in the management of patients with neovascular retinal diseases.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Select an initial anti-VEGF treatment approach for nAMD based on patient and disease factors
- Apply advanced management approaches for DME in the setting of residual fluid or poor adherence
- Determine when to extend treatment intervals in the management of RVO
Geeta Lalwani, MD
Rocky Mountain Retina Associates
Physician/Founder
Boulder, CO
Disclosures: Speakers Bureau: Apellis, Astellas, DORE, Genentech, Regeneron; Ownership Interests in Privately Held Companies: Ocugen
Alla Goldberg, MD
Northside Retina Specialists
Atlanta, GA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Alimera Sciences
Elite Bor-Shavit, MD
Vitreoretinal Specialist
D’Ambrosio Eye Care Inc.
Lancaster, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Genentech, Ocutrx, Regeneron
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information presented and apply their own clinical judgment when considering patient care decisions.
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
